I've research high blood pressure (hypertension for years) and have made
many casual observations on how and why this occurs.
Besides Nattokinase, which is a profoundly, beneficial substance (lowers BP, breaks down clots, thins the blood, removes calcium from arteries), there is also the very best natural substance I have ever encountered, which is called Ecklonia Cava (Seanol) found in a product called "Fibroboost."
I have used Fibroboost for well over a year and it is truly amazing.
Here's what it does:
- Relaxes arterial walls and increases blood flow by 50 to 60%
- Increases alpha waves, an indicator of relaxation (think of this as meditation in a capsule)
- Significantly reduces the formation of clots (or lowers fibrinogen levels), it thins the blood
- Potently suppresses ACE similar to the drug (enalapril) Vasotec, but better.
- Reduces artery inflammation and scrubs off artery plaque.
- About a 100 times more powerful than Green Tea Polyphenols, which means it fights free radicals.
- Increases levels of growth hormone. You can tell this works by how well you sleep during the night.
- Excellent for weight loss and prevents the formation of triglycerides, helps lean out the body.
Last, but not least, this will reduce blood pressure by way of the above mentioned mechanisms.
The recommended dose is one capsule twice per day.
This is how to obtain Fibroboost, click here
If you decide to order this, the following referral code will save $5 off the order: HIL335
In summary, if you were to take this Fibroboost along with Co-enzyme Q10 (Ubiquinol), Omega-3, Magnesium, and high dose-Vitamin D, your blood pressure should progressively improve in months time. Best off all, there are several meaningful and noticeable health benefits you may experience.
Nattokinase click here
Concentrated Fish oil, very high in EPA/DHA click here
Magnesium, this is a good form. Essential for blood pressure. click here
If you use this code, HIL335 you will save $5.00 off your first order.
How much to take?
Nattokinase should be taken twice per day.
Concentrated Fish oil (EPA/DHA), 2 to 4 softgels per day. Suggestion is two caps with your two of your largest meals.
Magnesium, 2 capsules twice per day.
All of these products furnish many health benefits. Better blood pressure is merely just one healthy benefit to expect.
There are many others.
Here's some information on Pycnogenol:
INTRODUCTION: Some compounds of herbal origin, such as Pycnogenol (PYC), have been considered as an aid in antiplatelet therapy. Pycnogenol, a French maritime pine bark extract, is a complex mixture of polyphenols that has the ability to reduce human smoking-induced platelet aggregation. The aim of this study was to evaluate the in vitro ability of PYC to improve the efficacy of acetylsalicylic acid (ASA) in the inhibition of platelet function. MATERIAL/METHODS: Whole blood, anticoagulated with hirudin, was drawn from 38 volunteers ( 40.4+/-13.8 years old) and incubated with PYC (10, 50, 100 microg/ml) or/and ASA (25, 100 micromol/l) for 20 min at RT.PYC was dissolved in water (water-PYC group, n=20) or ethanol (ethanol-PYC group, n=18). To investigate platelet functions, PFA-100 closure-time determination, whole-blood electrical aggregation (WBEA), and PRP aggregation were employed. Collagen (1 microg/ml) and ADP (5 micromol/l) were used as platelet agonists. RESULTS: A compounding effect of ASA and PYC to inhibit platelet function recorded in collagen-induced aggregation in PRP was observed, but only when ethanol-dissolved PYC was used. The inhibitory effect of PYC (alone) was most profound in platelets activated with ADP. At all concentrations, PYC significantly inhibited platelet aggregation only in the ethanol-PYC group. CONCLUSIONS: It was found that under in vitro conditions, ethanol-dissolved PYC deepened the efficacy of ASA to inhibit platelet function. This study confirmed the direct and compounding (with ASA) inhibitory effect of PYC on platelets. These observations encourage the concept that the combined use of ASA and PYC may be beneficial in patients with impaired response to ASA therapy.
-
Prevention of venous thrombosis and thrombophlebitis in long-haul flights with pycnogenol.
Belcaro G, Cesarone MR, Rohdewald P, Ricci A , Ippolito E , Dugall M, Griffin M, Ruffini I, Acerbi G , Vinciguerra MG , Bavera P , Di Renzo A , Errichi BM, Cerritelli F .Department of Biomedical Sciences, Irvine2 Vascular Lab, G D'Annunzio University and San Valentino Vascular Screening Project (Pe), Faculty of Motory Sciences, L'Aquila University, Italy. cardres@pe.abol.it
The aim of this study was to evaluate the occurrence of deep venous thrombosis (DVT) and superficial vein thrombosis (SVT) and its prophylaxis with an oral anti-edema and antithrombotic agent (Pycnogenol, Horphag, Research Management SA, Geneva, Switzerland) in long-haul flights, in subjects at moderate to high-risk of DVT and SVT. The study pre-included 244 pre-selected subjects; 211 were included (33 were excluded for several reasons due to logistic problems) and 198 completed the study; 13 subjects were lost for follow-up at the end of the flight, all for non-medical problems ( i.e., for difficult connections). All subjects were scanned within 90 minutes before the flight and within 2 hours after disembarking. Subjects were supplemented with 100 mg Pycnogenol per capsule. Treatment subjects received two capsules between 2 and 3 hours before flights with 250 mL of water; two capsules were taken 6 hours later with 250 mL of water and one capsule the next day. The control group received comparable placebo at the same intervals. The flight duration was on average 8 hours and 15 minutes (SD 55 min) (range, 7.45-12.33). In the control group there were five thrombotic events (one DVT and four superficial thromboses) while only nonthrombotic, localized phlebitis was observed in the Pycnogenol group (5.15% vs. no events; p<0.025 style="background-color: rgb(255, 255, 0);">No unwanted effects were observed. In conclusion, this study indicates that Pycnogenol treatment was effective in decreasing the number of thrombotic events (DVT and SVT) in moderate-to-high risk subjects, during long-haul flights.
-
Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity.
Department of Physiology and Biophysics, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
The vegetable cheese-like food, natto, is extremely popular in Japan with a history extending back over 1000 years. A fibrinolytic enzyme, termed nattokinase, can be extracted from natto; the enzyme is a subtilisin-like serine protease composed of 275 amino acid residues and has a molecular weight of 27.7 kDa. In vitro and in vivo studies have consistently demonstrated the potent pro-fibrinolytic effect of the enzyme. However, no studies to date have evaluated the effects of nattokinase on various hemorheological parameters and thus we have begun to assess the effects of the enzyme on RBC aggregation and blood viscosity. Blood samples were incubated with nattokinase (final activities of 0, 15.6, 31.3, 62.5 and 125 units/ml) for 30 minutes at 37 degrees C. RBC aggregation was measured using a Myrenne MA-1 aggregometer and blood viscosity assessed over 1-1000 s(-1) with a computer controlled scanning capillary rheometer (Rheolog). Our in vitro results showed a significant, dose-dependent decrease of RBC aggregation and low-shear viscosity, with these beneficial effects evident at concentrations similar to those achieved in previous in vivo animal trials. Our preliminary data thus indicate positive in vitro hemorheological effects of nattokinase, and suggest its potential value as a therapeutic agent and the need for additional studies and clinical trials.
Nattokinase for prevention of thrombosis
Tai and Sweet Am J Health Syst Pharm.2006; 63: 1121-1123
- Angiology. 2003 Sep-Oct;54(5):531-9.Links
-
Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized, controlled trial.
Cesarone MR, Belcaro G, Nicolaides AN, Ricci A , Geroulakos G , Ippolito E , Brandolini R , Vinciguerra G , Dugall M , Griffin M, Ruffini I, Acerbi G , Corsi M , Riordan NH, Stuard S, Bavera P, Di Renzo A, Kenyon J , Errichi BM .Department of Biomedical Sciences, Irvine2 Vascular Lab, G D'Annunzio University, San Valentino Vascular Screening Project (Pe), Pescara, Italy.
The aim of this study was to evaluate the development of edema, and superficial and deep vein thrombosis (DVT) prophylaxis with an oral profibrinolytic agent (Flite Tabs, 150 mg pinokinase, Aidan, Tempe, AZ, USA) in long-haul flights (7-8 hours), in high-risk subjects. A group of 300 subjects was included; 76 were excluded for several problems including concomitant treatments; 204 were randomized into 2 groups (active treatment or placebo) to evaluate the effects of prophylaxis with Flite Tabs. An exercise program was used in both groups. The femoral, popliteal, tibial, and superficial veins were scanned with ultrasound before and within 90 minutes after flights. Of the included subjects, 92 of 103 controls and 94 of 101 treated subjects completed the study. Dropouts were due to connection problems. Age, gender, and risk distribution were comparable in the groups. In the treatment group, no DVT was observed. In the control group, 5 subjects (5.4%) had a DVT and there were 2 superficial thromboses (7 events in 92 subjects; 7.6%). At inclusion, edema was comparable in the 2 groups. After flights there was an increase in score in controls (+12%) in comparison with a decrease (-15%) in the Flite Tabs group (the difference in variation was statistically significant). Intention-to-treat analysis for thrombotic events shows 18 failures in controls (11 lost to follow-up + 7 thrombotic events) of 92 subjects ( 19.6%) in comparison with 7 failures (of 94 subjects, equivalent to 7.4%) in the treatment group (p <>
-
Dietary supplementation with fermented soybeans suppresses intimal thickening.
Department of Pharmacology, Hamamatsu University School of Medicine, Shizuoka, Japan. yapplel@hama-med.ac.jp
Although soy foods have been consumed for more than 1000 y, it is only in the past 20 y that they have made inroads into Western diets. We investigated the effect of dietary supplementation with natto extracts produced from fermented soybeans on intimal thickening of arteries after vessel endothelial denudation. Natto extracts include nattokinase, a potent fibrinolytic enzyme having four times greater fibrinolytic activity than plasmin. Intimal thickening was induced in the femoral arteries by intravenous infusion of rose bengal followed by focal irradiation with a transluminal green light. Dietary natto extract supplementation was started 3 wk before endothelial injury and continued for another 3 wk after. In ex vivo studies, euglobulin clot lysis times were measured 3 wk after the initial supplementation. Neointima formation and thickening were also initiated successfully. The intima media ratio 3 wk after endothelial injury was 0.15 +/- 0.03 in the control group. Dietary natto extract supplementation suppressed intimal thickening (0.06 +/- 0.01; P < style="background-color: rgb(255, 255, 0);">hese findings suggest that natto extracts, because of their thrombolytic activity, suppress intimal thickening after vascular injury as a result of the inhibition of mural thrombi formation.
http://www.iherb.com/
http://www.iherb.com/
The first link is the deal I could find on the extended release Arginine, which is technically called Arginine Alpha-Ketoglutarate.
http://www.iherb.com/
The second link is a specific type of grape seed extract that has been shown in clinical studies to reduce blood pressure.
This is just as good as pine bark extract, but cheaper--it's also proven to work.
http://www.iherb.com/
Taking the two of these together should give a very positive effect.
No comments:
Post a Comment